Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Respiratory failure requiring mechanical ventilation due to COVID-19 induced pneumonia with confirmation via SARS-CoV-2 RT-PCR testing~* PaO2/FiO2 ratio \< 300 (or SpO2/FiO2 \< 315)~* Bilateral pulmonary infiltrates~Exclusion Criteria:~* Contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products).~* In the opinion of the site investigator or primary clinical care team, anticipated to die within 48 hours.~* Acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of less than 28 days unrelated to COVID-19 induced pneumonia (e.g.; stage IV malignancy, neurodegenerative disease, anoxic brain injury, etc.)~* Use of home oxygen at baseline~* Use of home mechanical ventilation at baseline (CPAP or BIPAP without need for oxygen is NOT an exclusion)~* Respiratory failure caused by illness other than SARS-CoV-2~* Other documented uncontrolled infection.~* More than 72 hours have elapsed since first meeting inclusion criteria~* Severe DIC, TTP, or antithrombin III deficiency needing factor replacement, FFP, cryoprecipitate.~* Patient is on Warfarin and it is deemed necessary to maintain therapeutic INR (because the CP will reverse the warfarin effect).~* On dialysis at the time enrollment is considered.~* Active intracranial bleeding.~* Clinically significant myocardial ischemia.~* Prisoner or Incarceration~* Pregnancy or active breast feeding~* Has already received convalescent plasma for COVID-19 infection during current admission~* Current participation in another interventional research study~* Inability or unwillingness of subject or legal surrogate/representative to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intubated COVID-19 patients in the ICU (Type: EXPERIMENTAL): Mechanically ventilated intubated patients with respiratory failure due to COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).